FindTrial
Sign In

Antibiotic Treatment Trial in Acute Coronary Syndrome

Status
Not yet recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-522136-14-00
Enrollment
1070
Registered
2025-08-27
Start date
Unknown
Completion date
Unknown
Last updated
2025-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-ST-elevation myocardial infarction (NSTEMI), ST-elevation myocardial infarction (STEMI), coronary artery disease

Brief summary

Major adverse cardiac and cerebrovascular events (MACCE) in 12 months follow-up, including: cardiovascular death, myocardial infarction, hospitalization for NYHA IV heart failure, stroke or transient ischemic attack (TIA)

Detailed description

Individual components of the primary end point at 12 months, MACCE at 3 months, MACCE at 2 and 5 years

Interventions

DRUGCeftriaxon Navamedic 2 g infuusiokuiva-aine
DRUGliuosta varten
DRUGAmoxin 500 mg kalvopäällysteinen tabletti

Sponsors

TAYS Sydaenkeskus Oy
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Major adverse cardiac and cerebrovascular events (MACCE) in 12 months follow-up, including: cardiovascular death, myocardial infarction, hospitalization for NYHA IV heart failure, stroke or transient ischemic attack (TIA)—

Secondary

MeasureTime frame
Individual components of the primary end point at 12 months, MACCE at 3 months, MACCE at 2 and 5 years—

Countries

Finland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026